U.S. FDA Grants Priority Review for Genentech’s Enspryng for MOGAD, an Autoimmune Disease With No Approved Treatments
Go back to U.S. FDA Grants Priority Review for Genentech’s Enspryng for MOGAD, an Autoimmune Disease With No Approved Treatments| Chugai Pharmaceutical Ltd Unsponsored ADR (AMEX: CHGCY) | Delayed: 21.50 +0.10 (0.47%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $21.40 | 52 Week High | $74.63 | |||
| Open | $21.17 | 52 Week Low | $56.80 | |||
| Day High | $21.61 | P/E | N/A | |||
| Day Low | $20.67 | EPS | $0.00 | |||
| Volume | 219,494 | |||||
| Roche Holding AG Basel American Depositary Shares (AMEX: RHHBY) | Delayed: 54.15 -0.48 (0.88%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $54.63 | 52 Week High | $35.13 | |||
| Open | $54.60 | 52 Week Low | $28.10 | |||
| Day High | $54.90 | P/E | N/A | |||
| Day Low | $54.00 | EPS | $0.00 | |||
| Volume | 1,091,681 | |||||
